Quantum is partnering with Massachusetts General Hospital on a clinical study to test a PET tracer for monitoring response to treatment in MS.

progressive multiple sclerosis, and chronic pain. In December 2024, the company dosed the first subject cohort in the Phase Ib positron emission tomography (PET) trial of brain-penetrant small ...

Researchers at UCL have developed an innovative AI tool called MindGlide, designed to transform the way MS treatments are ...

Researchers hope MindGlide will unlock valuable information from millions of untapped brain images that were previously difficult or impossible to understand.

announced a joint clinical study with Massachusetts General Hospital to evaluate a novel PET imaging technique for tracking myelin integrity in multiple sclerosis (MS) patients. The study will ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...